Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
RCT on the Efficacy of Dexamethasone Versus Methyl Prednisolone in Covid-19 Infected Patients With High Oxygen Flow
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 60
- Registration Number
- NCT05062681
- Locations
- 🇪🇬
Eman Osama, Cairo, Egypt
Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide
- Conditions
- Interventions
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 60
- Registration Number
- NCT05060627
- Locations
- 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸Hospital Germans Trias i Pujol (ICO BADALONA), Badalona, Spain
🇪🇸Hospital Clinic, Barcelona, Spain
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.
- Conditions
- Interventions
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 100
- Registration Number
- NCT05049473
- Locations
- 🇪🇸
Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸Hospital del Mar, Barcelona, Spain
🇪🇸ICO-Hospital Duran i Reynals, Bellvitge, Spain
Marizomib Central Nervous System (CNS)
- Conditions
- Interventions
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT05050305
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL
- Conditions
- Interventions
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT05036577
- Locations
- 🇨🇳
Department of Hematology, Huashan Hospital, Fudan University, Shanghai, Shanghai, China
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT05032183
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
ESP Block vs Control for Pain Control Following Percutaneous Nephrolithotomy
- Conditions
- Interventions
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- University of Tennessee Medical Center
- Target Recruit Count
- 128
- Registration Number
- NCT05024344
- Locations
- 🇺🇸
University of Tennessee Medical Center, Knoxville, Tennessee, United States
A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus DXM in Treatment of ITP
- Conditions
- Interventions
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2021-08-27
- Lead Sponsor
- Shandong University
- Target Recruit Count
- 106
- Registration Number
- NCT05023915
- Locations
- 🇨🇳
Qilu hospital (Qingdao), Shandong University, Qingdao, Shandong, China
🇨🇳Qilu hospital, Shandong University, Jinan, Shandong, China
MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 761
- Registration Number
- NCT05020236
- Locations
- 🇺🇸
MSK Bergen, Montvale, New Jersey, United States
🇺🇸MSK Commack, Commack, New York, United States
🇺🇸MSK Westchester, Harrison, New York, United States
Venetoclax Plus Inotuzumab for B-ALL
- Conditions
- Interventions
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 26
- Registration Number
- NCT05016947
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.